Friday, 21 April 2017

FDA approves Samsung Bioepis' copy of J&J's Remicade: company

SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade, the first drug developed by the Samsung Group unit approved in the United States.


No comments:

Post a Comment